Vaccines manufactured at Moderna’s state-of-the-art Canadian mRNA facility to be prepared and packaged at Novocol’s Ontario-based facility Fill-finish agreement will secure domestic end-to-end vaccine production and ensures rapid response capabilities for future pandemic readiness for Canadians TORONTO-Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a long-term agreement with Ontario-based Novocol Pharma, a leading …